Drug Approval | July 01, 2022
Lupin receives approval from USFDA for Paliperidone extended-release tablets
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
The settlement and dismissal resolves all claims between the parties
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Brings 25 years of global operations and supply chain experience to Piramal
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Subscribe To Our Newsletter & Stay Updated
